Treatment with buprenorphine is approved and effective for adolescents with opioid use disorder (OUD) but is underused. JAMA Pediatrics Editor in Chief Dimitri Christakis, MD, and JAMA Pediatrics Associate Editor Alison A. Galbraith, MD, discuss diagnosis and treatment of OUD with Scott Hadland, MD, Chief of Adolescent Medicine at Massachusetts General Hospital, Boston, and an expert in adolescent OUD.  Related Content: Out-of-Pocket Costs and Payer Types for Buprenorphine Among US Youth Aged 12 to 19 Years Conflict of Interest disclosures: Dr Hadland has received honoraria from the American Academy of Pediatrics for speaking on the topic of adolescent opioid use disorder treatment.